Synpromics announces £5.2M British investment in gene therapy tech

By Flora Southey

- Last updated on GMT

image: iStock
image: iStock

Related tags Dna

Scottish synthetic biology firm Synpromics has received £5.2M ($6.6M) to enhance its synthetic promoter design technology used in gene therapy development.

Funding sources include UK-based companies Calculus Capital, the Scottish Investment Bank, the investment branch of Scottish Enterprise, and private shareholders.

The majority of resources will fund the development of Synpromics’ synthetic promoters – DNA sequences that do not exist in nature – via the company’s PromPT design platform.

PromPT is a bioinformatics database for the design, build and screening of synthetic promoters. The promoters allow for precise control of gene function, impacting gene therapy, cell therapy and gene editing.

Synpromics CEO David Venables described the distinct nature of the PromPT platform late last year​ as a “unique capability for the industrialised development of synthetic promoters which doesn’t exist elsewhere.”

Beginning with a team of nine, Synpromics predicts its increase staff size to increase to up to 35 over the next 12 to 18 months.

The deal follows GE Healthcare’s investment​ in the Scottish company earlier this year.

Related news

Show more

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers

Follow us

Webinars

Headlines